Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation.

European journal of haematology - 1 Dec 2015

Kobayashi Masato, Kuroki Shiori, Tanaka Yu, Moriya Yukari, Kozutumi Yukari, Uehara Yuji, Ono Kenichiro, Tamura Kyoichi, Washizu Tsukimi, Bonkobara Makoto

Abstract excerpt

Although imatinib has therapeutic activity for certain subsets of patients with mastocytosis, it is not always curative. Here, molecular mechanisms that confer imatinib resistance to neoplastic mast cells were investigated using an imatinib-sensitive canine neoplastic mast cell line VI-MC carrying a KIT c.1523A>T activating mutation. Two imatinib-resistant sublines were established by culturing VI-MC cells in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dogs
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Extracellular Signal-Regulated MAP Kinases

Share to Imatinib Mesylate

Share to Mastocytosis

Share to Proto-Oncogene Proteins c-akt

Share to Proto-Oncogene Proteins c-kit

Share to STAT3 Transcription Factor

Source

Identifiers

PMID: 25684098
DOI: 10.1111/ejh.12526

Genes

KIT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation.PMID 25684098Read ↗

Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation.Semantic proximity Read ↗

NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation.Semantic proximity Read ↗

Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy.Semantic proximity Read ↗

Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.Semantic proximity Read ↗

A decrease in ubiquitination and resulting prolonged life-span of KIT underlies the KIT overexpression-mediated imatinib resistance of KIT mutation-driven canine mast cell tumor cells.Semantic proximity Read ↗

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.Semantic proximity Read ↗

Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells.Semantic proximity Read ↗

Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatmentSemantic proximity Read ↗

Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 <i>KIT</i> mutations and review of the literatureSemantic proximity Read ↗

Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours.Semantic proximity Read ↗

Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation.Semantic proximity Read ↗

Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.